Skip to main content
OpenTrials
Completed

NCT Number: NCT03279939

Evaluation of Heidelberg Engineering SPECTRALIS With OCT Angiography Module

Assessment of image quality and clinical relevance of OCT Angiography via comparison to FA/ICGA.

Completed

Looking for future studies?

Notify Me

Key information

Age range

22 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Retina Consultants of Houston

Houston, Texas, 77030, United States

About this study

The objectives of this study are:

  • To compare the OCTA image quality between the SPECTRALIS and the predicate.
  • To compare the agreement of clinical findings on SPECTRALIS OCTA to the predicate.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

All subjects:

  • Able and willing to undergo the test procedures, sign informed consent, and follow instructions.
  • Age ≥ 22

Subjects with Normal Eyes:

  • Subjects presenting at the site without uncontrolled systemic conditions, or ocular disease, as determined by the Investigator
  • Corrected visual acuity ≥ 20/40 in each eye
  • No history of ocular surgical intervention (except for refractive or cataract surgery) in either eye

Subjects with Pathology:

  • Subjects with retinal conditions in at least one eye.
  • Subjects included can have a range of retinal vascular pathologies affecting different anatomic depths through the retina and choroid. Retinal conditions including but not limited to diabetic retinopathy, wet age-related macular degeneration (AMD), and branch or central retinal vein occlusion that give rise to features such as retinal ischemia, microaneurysms, choroidal neovascularization and retinal neovascularization will be included.

Exclusion criteria

  • Subjects unable to read or write
  • Subjects with ocular media not sufficiently clear to obtain acceptable study-related imaging
  • Subjects who cannot tolerate the imaging procedures
  • Subjects with known allergies to fluorescein dye, Indocyanine Green (ICG), shellfish, drugs for pupillary dilation
  • Subjects with contraindication to pupillary dilation in study eye

Treatment and study plan

OCT Angiography

Device

OCT Angiography offers clinicians a non-invasive three-dimensional visualization of vasculature in the retina and choroid. The visualization of perfused vasculature in a three-dimensional layout, offers clinicians an aid in the identification of retinal and choroidal pathologies such as retinal ischemia, microaneurysms, retinal neovascularization and choroidal neovascular membranes.

Other names: OCTA

Color Fundus Photography

Device

Non-contact white light photography.

Other names: CFP

Fluorescein Angiography

Device

An imaging procedure where dye is injected into a vein and images are taken of the back of the eye to visualize the perfusion of retinal vessels in two dimensional images.

Other names: FA

Indocyaine Green Angiography

Device

An imaging procedure where dye is injected into a vein and images are taken of the back of the eye to visualize the perfusion of choroidal vessels in two dimensional images.

Other names: ICGA

Primary outcomes

  1. OCTA image quality

    Time frame: day 1

    Image quality grading results of study selected images

  2. Clinically relevant findings on OCTA

    Time frame: day 1

    Clinically relevant grading results of study selected images

Sponsors and collaborators

Lead sponsor

Heidelberg Engineering GmbH

Industry

Registry information

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Sep 12, 2017
Registry last updated
Sep 15, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.